Discrete changes in circulating regulatory T cells during infliximab treatment of Crohn's disease

References

• Abraham C, Cho J. IL-23 and autoimmunity: New insights into the pathogenesis of inflammatory bowel disease. Ann Rev Med. 2009; 60:85–96.
   Google Scholar
• Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004; 199:971–979.
   PubMed Web of Science ®Google Scholar
• Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Sanz M, Exley M, Wilson B, Porcelli S, Maclaren N. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 2002; 109:131–140.
   PubMed Web of Science ®Google Scholar
• Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med. 2004; 200:277–285.
   PubMed Web of Science ®Google Scholar
• Meier C, Plevy S. Therapy insight: How the gut talks to the joints—Inflammatory bowel disease and the spondyloarthropathies. Nat Clin Pract Rheumatol. 2007; 3:667–674.
   PubMedGoogle Scholar
• Nadkarni S, Mauri C, Ehrenstein MR. Anti-TNF-alpha therapy induces a distinct regulatory T-cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007; 204:33–39.
   PubMed Web of Science ®Google Scholar
• Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994; 344:1105–1110.
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, Van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med. 1997; 337:1029–1035.
   PubMed Web of Science ®Google Scholar
• Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, Nakamura T, Koganei K, Fukushima T, Watanabe M. CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol. 2004; 173:3119–3130.
   PubMed Web of Science ®Google Scholar
• Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann R. Peripheral and intestinal regulatory CD4+CD25high T cells in inflammatory bowel disease. Gastroenterology. 2005; 128:1868–1878.
   PubMed Web of Science ®Google Scholar
• Kelsen J, Agnholt J, Hoffmann HJ, Rømer JL, Hvas CL, Dahlerup JF. FoxP3+CD4+CD25+T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease. Clin Exp Immunol. 2005; 141:549–557.
   PubMed Web of Science ®Google Scholar
• Saruta M, Yu QT, Fleshner PR, Mantel PY, Schmidt-Weber CB, Banham AH, Papadakis KA. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol. 2007; 125:281–290.
   PubMed Web of Science ®Google Scholar
• Ricciardelli I, Lindley KJ, Londei M, Quaratino S. Anti tumour necrosis-alpha therapy increases the number of FOXP3(+) regulatory T cells in children affected by Crohn's disease. Immunology. 2008; 125:178–183.
   PubMed Web of Science ®Google Scholar
• Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS, Levings MK. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology. 2008; 125:145–153.
   PubMed Web of Science ®Google Scholar
• Faubion WA, De Jong YP, Molina AA, Ji H, Clarke K, Wang B, Mizoguchi E, Simpson SJ, Bhan AK, Terhorst C. Colitis is associated with thymic destruction attenuating CD4+25+ regulatory T cells in the periphery. Gastroenterology. 2004; 126:1759–1770.
   PubMedGoogle Scholar
• Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, Gasche C, Tilg H, Schreiber SW, Scholmerich J, Reinisch W. European evidence based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Gut. 2006; 55 Suppl 1: i1–15.
   PubMed Web of Science ®Google Scholar
• Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980; 1:514.
   PubMed Web of Science ®Google Scholar
• Best WR. Predicting the Crohn's disease activity index from the Harvey–Bradshaw index. Inflamm Bowel Dis. 2006; 12:304–310.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Savilahti E, Karkkainen P, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis. 2008; 14:1392–1398.
   PubMed Web of Science ®Google Scholar
• Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood. 2007; 110:2983–2990.
   PubMed Web of Science ®Google Scholar
• Aerts NE, Dombrecht EJ, Ebo DG, Bridts CH, Stevens WJ, De Clerck LS. Activated T cells complicate the identification of regulatory T cells in rheumatoid arthritis. Cell Immunol. 2008; 251:109–115.
   PubMed Web of Science ®Google Scholar
• Cornillie F, Shealy D, D'Haens G, Geboes K, van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther. 2001; 15:463–473.
   PubMed Web of Science ®Google Scholar
• Vigna-Perez M, Abud-Mendoza C, Portillo-Salazar H, Alvarado-Sanchez B, Cuevas-Orta E, Moreno-Valdes R, Baranda L, Paredes-Saharopulos O, Gonzalez-Amaro R. Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol. 2005; 141:372–380.
   PubMed Web of Science ®Google Scholar
• Dombrecht EJ, Aerts NE, Schuerwegh AJ, Hagendorens MM, Ebo DG, Van Offel JF, Bridts CH, Stevens WJ, De Clerck LS. Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis. Clin Exp Rheumatol. 2006; 24:31–37.
   PubMedGoogle Scholar
• Sempere-Ortells JM, Perez-Garcia V, Marin-Alberca G, Peris-Pertusa A, Benito JM, Marco FM, Zubcoff JJ, Navarro-Blasco FJ. Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to disease activity score-28. Autoimmunity. 2009; 1.
   Google Scholar
• van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: Differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 2004; 50:2775–2785.
   PubMed Web of Science ®Google Scholar
• Mottonen M, Heikkinen J, Mustonen L, Isomaki P, Luukkainen R, Lassila O. CD4+CD25+T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol. 2005; 140:360–367.
   PubMed Web of Science ®Google Scholar
• Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, Tannapfel A, Fontenot JD, Ramsdell F, Powrie F. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+T cells during cure of colitis. J Immunol. 2006; 177:5852–5860.
   PubMedGoogle Scholar
• Holmen N, Lundgren A, Lundin S, Bergin AM, Rudin A, Sjovall H, Ohman L. Functional CD4+CD25high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis. 2006; 12:447–456.
   PubMed Web of Science ®Google Scholar
• Maloy KJ. The Interleukin-23/Interleukin-17 axis in intestinal inflammation. J Intern Med. 2008; 263:584–590.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4:330–336.
   PubMed Web of Science ®Google Scholar
• Bacchetta R, Passerini L, Gambineri E, Dai M, Allan SE, Perroni L, Dagna-Bricarelli F, Sartirana C, Matthes-Martin S, Lawitschka A, Azzari C, Ziegler SF, Levings MK, Roncarolo MG. Defective regulatory and effector T-cell functions in patients with FOXP3 mutations. J Clin Invest. 2006; 116:1713–1722.
   PubMed Web of Science ®Google Scholar
• Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van LM, Buckner JH, Ziegler SF. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+. J Clin Invest. 2003; 112:1437–1443.
   PubMed Web of Science ®Google Scholar
• Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St GB. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006; 203:1693–1700.
   PubMed Web of Science ®Google Scholar
• Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St GB, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+T reg cells. J Exp Med. 2006; 203:1701–1711.
   PubMed Web of Science ®Google Scholar
• Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol. 2007; 19:345–354.
   PubMed Web of Science ®Google Scholar
• Maurice MM, van der Graaff WL, Leow A, Breedveld FC, van Lier RA, Verweij CL. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum. 1999; 42:2166–2173.
   PubMed Web of Science ®Google Scholar
• Meenan J, Spaans J, Grool TA, Pals ST, Tytgat GN, Van Deventer SJ. Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation. Gut. 1997; 40:241–246.
   PubMed Web of Science ®Google Scholar
• Hart AL, Kamm MA, Knight SC, Stagg AJ. Quantitative and functional characteristics of intestinal-homing memory T cells: Analysis of Crohn's disease patients and healthy controls. Clin Exp Immunol. 2004; 135:137–145.
   PubMed Web of Science ®Google Scholar
• Salmi M, Jalkanen S. Molecules controlling lymphocyte migration to the gut. Gut. 1999; 45:148–153.
   Google Scholar